EXPLORE!

FDA Approves Yorvipath for Hypoparathyroidism

  427 Views

Emedinexus    03 April 2025

The U.S. Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide) for subcutaneous use in adults with hypoparathyroidism. This treatment addresses the insufficient production of parathyroid hormone, which can lead to low calcium levels.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.